Clinical Stage Drug Discovery Based on Our Proprietary Platform Technology

SMNH: Delivering Novel Chemistry Solutions for Today's Diseases

SB 9200: A Potential Breakthrough Drug for HBV

Latest News

    • 06 SEP 16

    Spring Bank Pharmaceuticals Abstracts on STING Agonist SB 11285 Accepted for Poster Presentations at AACR Special Conference on Tumor Immunology and Immunotherapy

    HOPKINTON, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced that two abstracts related to SB 11285, the Company’s novel, proprietary STING agonist compound for immuno-oncology, have been accepted for poster presentations at the upcoming American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy taking place on October 20-23, 2016 at the Boston Marriott Copley Place in Boston, MA. These abstracts highlight the potent immune-modulating and anti-…

    Read more →
    • 22 AUG 16

    Spring Bank Pharmaceuticals, Inc. to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City on September 13th, 2016

    HOPKINTON, Mass., Aug. 22, 2016 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, today announced it will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 13th at 11:40 am ET. Martin Driscoll, President and CEO of Spring Bank Pharmaceuticals, will provide an overview of the Company’s business during the live presentation and Jon Freve, CFO, will also be in attendance.

    In addition to the presentation, management will be available to participate in one-on-one meetings with qual…

    Read more →